×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Articles

Katie Kosko
With no peer support, nor any guidance on how to navigate this part of the disease, Casperson started a blog. Through this, she connected with other survivors.
Brielle Urciuoli
The Food and Drug Administration (FDA) approved Rubraca (rucaparib) as a maintenance therapy for women with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy, according to Clovis Oncology, the company that manufactures the drug.  
Kristie L. Kahl
Israeli study shows cannabis is safe and effective for the palliative treatment of patients with cancer.
Kristie L. Kahl
Despite exciting developments of PARP inhibitors over the years, limited knowledge exists in the mechanism of PARP-7 and its potential effect in targeted therapy for patients with ovarian cancer.
Kevin Klasila
For the past four years, a coworker and I took on the responsibility as organizers and ambassadors for the annual Movember “Best Moustache” competition and fundraising event in our office. In November 2016, the cause took on a whole new meaning.
Kristie L. Kahl
The Food and Drug Administration (FDA) granted priority review to dacomitinib for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR-activating mutations, according to Pfizer, the drug’s manufacturer.
Brielle Urciuoli
The potential approval offers hope to the rare blood cancer, which currently has no standard of care treatment protocol.
Brielle Urciuoli
Although the amount of treatment options for the frontline setting of multiple myeloma may be limited, extensive research is helping these efforts along.
Kristie L. Kahl
Following fertility clinic malfunctions in Cleveland and San Francisco, many patients who have or had cancer are facing devastating losses, leaving many questions in the wake of these events.
Brielle Urciuoli
Simply knowing who to screen, and when, could reduce myeloma-related mortality rates, according to recent research.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment

Caregiver

Healthcare Professional

Not Applicable